The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation
By D. Singer, Yuchiao Chang, M. Fang, Leila H. Borowsky, N. Pomernacki, N. Udaltsova, Alan S. Go. Annals of Internal Medicine, 2009
625 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Neurology
View Paper: https://www.semanticscholar.org/paper/5cfd59167700ef79366f384f7438cc0076585dc6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial (2013, result): “In the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) cohort of >7000 patients with nonvalvular AF receiving warfarin in routine clinical practice, this metric was 14%.(20) Over 2 years, the warfarin discontinuation rate in the control group (16%) was similar to that in the RE-LY tr”